Prescribing information

 

Prescribing information

_________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Three-part virtual meeting series.

The role of TPO-RAs in blood disorders

In this three-part series, expert haematologists will discuss the use of TPO-RAs in ITP and SAA. There will be presentations, debates and case studies from leaders in the field, with time for you to be able to ask questions. The sessions are open to all clinicians working in haematology and are accessible via the registration sites below.

Dr. Drew Provan vs. Dr. Vickie McDonald, Royal London Hospital

This house believes; TPO-RAs vs. immunosuppression after steroid failure in ITP

Dr. Drew Provan vs. Dr. Vickie McDonald, Royal London Hospital

Monday 12th October 2020, 17:00

Register here

 

Dr. Ronan Desmond, Tallaght University Hospital, Dublin

How to manage the refractory acquired SAA patient– a guide to diagnosing, managing and monitoring

Dr. Ronan Desmond, Tallaght University Hospital, Dublin

Tuesday 17th November 2020, 17:00

Register here

 

Chair: Dr. Drew Provan, Royal London Hospital Panel: Dr. Quentin Hill, Leeds, Dr. Vickie McDonald, Royal London Hospital, Rosie Davies, Haematology Nurse Specialist, Liverpool

ITP in the real world; a multidisciplinary approach

Chair: Dr. Drew Provan, Royal London Hospital
Panel: Dr. Quentin Hill, Leeds, Dr. Vickie McDonald, Royal London Hospital, Rosie Davies, Haematology Nurse Specialist, Liverpool

Monday 14th December 2020, 17:00

Register here

 

Post-meeting

After the meeting, the presentation slides and a recording of the meeting will be available for a limited time to registered users on this site to refer back to.

Our promise

Novartis is truly committed to providing world-class education to our UK healthcare professionals. We recognise the value this meeting brings to a vast range of physicians including registrars, nurses, pharmacists and consultants. We hope that you can join us for this meeting series.

 

Indication: REVOLADE is indicated for the treatment of patients aged 1 year and above with primary ITP lasting 6 months or longer from diagnosis and who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).1
REVOLADE is indicated in adult patients with chronic HCV infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy.1
REVOLADE is indicated in adult patients with acquired SAA who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation.1

This meeting is organised and funded by Novartis Pharmaceuticals UK Ltd and will contain company product information. Prescribing information will also be available at this meeting.

Abbreviations: HCV, hepatitis C virus; ITP, immune thrombocytopenia; SAA, severe aplastic anaemia; TPO-RA, thrombopoietin-receptor agonist.

Reference     

  1. REVOLADE Summary of Product Characteristics.
HCP20-C049 September 2020

For more information, refer to the REVOLADE® (eltrombopag olamine) Summary of Product Characteristics: https://www.medicines.org.uk/emc/product/7819/smpc

Legal Category: POM.

Aluminium blisters (PA/Alu/PVC/Alu) in a carton containing 14 or 28 film-coated tablets and multipacks containing 84 (3 packs of 28) film-coated tablets. Marketing Authorisation (MA) number, quantities and NHS price: EU/1/10/612/002 – 25 mg x 28 tablet pack £770, EU/1/10/612/005 – 50 mg x 28 tablet pack £1540, EU/1/10/612/008 – 75 mg x 28 tablet pack £2310

 

×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]